Literature DB >> 15001582

Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003.

Zvi Laron1.   

Abstract

Clinical and laboratory investigations starting in 1958 of a group of dwarfed children resembling isolated GH deficiency but who had very high serum levels of GH led to the description of the syndrome of primary GH resistance or insensitivity (Laron syndrome) and subsequently to the discovery of its molecular defects residing in the GH receptor and leading to an inability of IGF-I generation. With the biosynthesis of IGF-I in 1986, therapeutic trials started. Continuously more and more patients are being diagnosed in many parts of the world with a variety of molecular defects. This syndrome proved to be a unique model that enables the study of the consequences of GH receptor defects, the physiopathology of GH-IGF-I disruption, and comparison of the GH-independent IGF-I effects. This review presents the personal experience gained from the study follow-up and treatment of the 60 patients followed up for many years in the Israeli cohort.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001582     DOI: 10.1210/jc.2003-031033

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  82 in total

Review 1.  Growth hormone during development.

Authors:  Joy Osafo; Yuhong Wei; Gurvinder Kenth; Cynthia Gates Goodyer
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

2.  The globe and orbit in Laron syndrome.

Authors:  L Kornreich; O Konen; P Lilos; Z Laron
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-14       Impact factor: 3.825

3.  Evolution of receptors for growth hormone and somatolactin in fish and land vertebrates: lessons from the lungfish and sturgeon orthologues.

Authors:  Shoji Fukamachi; Axel Meyer
Journal:  J Mol Evol       Date:  2007-10-05       Impact factor: 2.395

Review 4.  Growth Hormone Deficiency: Health and Longevity.

Authors:  Manuel H Aguiar-Oliveira; Andrzej Bartke
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

5.  Growth hormone (GH-1) gene deletions in children with isolated growth hormone deficiency (IGHD).

Authors:  Meena P Desai; Shilpa M Mithbawkar; Pradnya S Upadhye; Kavita K Shalia
Journal:  Indian J Pediatr       Date:  2011-10-21       Impact factor: 1.967

Review 6.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

7.  Rapid method for growth hormone receptor exon 3 delete (GHRd3) SNP genotyping from archival human placental samples.

Authors:  Rebecca A Pelekanos; Varda S Sardesai; Marloes Dekker Nitert; Leonie K Callaway; Nicholas M Fisk; Penny L Jeffery
Journal:  Endocrine       Date:  2015-06-12       Impact factor: 3.633

8.  Abnormalities of the axial and proximal appendicular skeleton in adults with Laron syndrome (growth hormone insensitivity).

Authors:  L Kornreich; O Konen; M Schwarz; Y Siegel; G Horev; I Hershkovitz; Z Laron
Journal:  Skeletal Radiol       Date:  2007-11-09       Impact factor: 2.199

9.  Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.

Authors:  Daniela Concolino; Gianluca Muzzi; Simona Sestito; Giovanna Vega; Giuseppe Bonapace; Pietro Strisciuglio
Journal:  Eur J Pediatr       Date:  2009-06-11       Impact factor: 3.183

10.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.